AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 4040500
Drug: OKY‐1581 treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OKY‐1581 treatment
Trial: 24685536
Drug: Therapist-delivered cognitive
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapist-delivered cognitive behavioural therapy session (CB-Education)
Trial: 19435959
Drug: Fenofibrate +
RxNorm normalized name: Fenofibrate
DrugBank: Fenofibrate (DB01039)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fenofibrate + Metformin
Trial: 11685031
Drug: Erythromycin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin (1 mg/kg every 8 hours for 14 days)
Trial: 11685031
Drug: Control (H2-receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (H2-receptor antagonists and gastrokinetic drugs)
Trial: 2239303
Drug: VP-16 combined
RxNorm normalized name: etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: VP-16 combined with other anti-tumor agents
Trial: 19267963
Drug: Matched-taper single-cone
RxNorm normalized name: Pinus strobus cone extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched-taper single-cone obturation
Trial: 17112804
Drug: Ezetimibe (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezetimibe (20 mg orally)
Trial: 11248608
Drug: Tolterodine IR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolterodine IR 2 mg twice daily
Trial: 11248608
Drug: Tolterodine ER
RxNorm normalized name: tolterodine Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolterodine ER 4 mg once daily and Tolterodine IR 2 mg twice daily
Trial: 9227717
Drug: Pranlukast, 450
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pranlukast, 450 mg twice daily
Trial: 8039526
Drug: Active approach
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active approach to pharmacological treatment
Trial: 22943848
Drug: Conventional lit-end
RxNorm normalized name: End-Zit
DrugBank: Octasulfur (DB09353)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional lit-end cigarettes (CC)
Trial: 18498913
Drug: Single-dose memantine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose memantine 5 mg
Trial: 18498913
Drug: Single-dose memantine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose memantine 10 mg
Trial: 18498913
Drug: Single-dose memantine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose memantine 20 mg
Trial: 18498913
Drug: Multiple-dose memantine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple-dose memantine 5 mg once daily for 14 days
Trial: 15941893
Drug: Glutamine supplementation
RxNorm normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glutamine supplementation (0.3 g . kg(‐1) . d(‐1))
Trial: 10562579
Drug: Sulindac 150
RxNorm normalized name: sulindac 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulindac 150 mg orally twice a day for three months (n=10)
Trial: 8712447
Drug: Epidural clonidine
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epidural clonidine (targeted to 50, 100, 200, or 400 ng/ml)
Trial: 8712447
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of neostigmine and clonidine
Trial: 1910342
Drug: FCH-free, NTG-containing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FCH-free, NTG-containing spray (0.8 mg NTG)
Trial: 1910342
Drug: FCH- and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FCH- and NTG-containing spray (0.8 mg NTG)
Trial: 1910342
Drug: Placebo (FCH-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (FCH- and NTG-free spray, 2 puffs)
Trial: 25238031
Drug: Full-arch implant-fixed
RxNorm normalized name: arched swimming crab, cooked preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full-arch implant-fixed prostheses (G1)
Trial: 25238031
Drug: Multiple implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple implant splinting via acrylic resin denture bases (G2)
Trial: 22944060
Drug: Domestic rosuvastatin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Domestic rosuvastatin, 10 mg/day
Trial: 22944060
Drug: CRESTOR, 10
RxNorm normalized name: Crestor, 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CRESTOR, 10 mg/day
Trial: 11915378
Drug: Indocyanine green
RxNorm normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Indocyanine green (ICG) 12.5 mg
Trial: 11915378
Drug: Indocyanine green
RxNorm normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Indocyanine green (ICG) 25 mg
Trial: 9793701
Drug: Subcutaneous sumatriptan
RxNorm normalized name: Sumatriptan
DrugBank: Sumatriptan (DB00669)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subcutaneous sumatriptan for treating migraine attacks
Trial: 1977980
Drug: Antibiotic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic treatment (metronidazole 20 mg/kg or 5 mg/kg daily, amoxycillin 25 mg/kg daily)
Trial: 28976
Drug: 1.0 mg
RxNorm normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg 15(S)15-methyl PGF2alpha methyl ester pessaries every 3 hours (maximum 4 doses)
Trial: 28976
Drug: 1.5 mg
RxNorm normalized name: boron 1.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg 15(S)15-methyl PGF2alpha methyl ester pessaries every 3 hours (maximum 4 doses)
Trial: 28976
Drug: Both doses
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both doses (1.0 mg and 1.5 mg)
Trial: 31788995
Drug: 4-weekly carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 4-weekly carboplatin area under the curve 4 and pegylated liposomal doxorubicin (PLD) 30 mg/m², n=24
Trial: 31788995
Drug: 4-weekly carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 4-weekly carboplatin area under curve 4 and pegylated liposomal doxorubicin (PLD) 30 mg/m², n=24
Trial: 12745614
Drug: Intrathecal BDNF
RxNorm normalized name: BDNF, human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal BDNF therapy
Trial: 10784225
Drug: Human soluble
RxNorm normalized name: Recombinant human soluble insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human soluble insulin (Humulin S)
Trial: 1329477
Drug: Once-daily lisinopril
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily lisinopril (5-20 mg)
Trial: 1329477
Drug: Twice-daily captopril
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily captopril (12.5-50 mg)
Trial: 28042578
Drug: Aromatherapy (inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aromatherapy (inhalation of a blend of 1.0 mL of lemon and 0.5 mL of ginger essential oils)
Trial: 28042578
Drug: Control (inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (inhalation of distilled water as placebo)
Trial: 22274951
Drug: Palonosetron 0.25
RxNorm normalized name: palonosetron 0.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palonosetron 0.25 mg intravenously on days 1 and 4 (schedule 1)
Trial: 22274951
Drug: Palonosetron 0.25
RxNorm normalized name: palonosetron 0.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palonosetron 0.25 mg intravenously on days 1, 3, and 5 (schedule 2)
Trial: 22274951
Drug: Both dosing
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both dosing schedules of palonosetron
Trial: 20637970
Drug: Avanafil 50
RxNorm normalized name: avanafil 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avanafil 50 mg
Trial: 20637970
Drug: Avanafil (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avanafil (all doses)
Trial: 19099009
Drug: GW406381 (1,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GW406381 (1, 5, 10, 25, or 50 mg)
Trial: 16400293
Drug: Newer drugs
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Newer drugs (lamotrigine, levetiracetam, topiramate, zonisamide)
Trial: 16400293
Drug: Drug combinations,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug combinations, vagal nerve stimulation, felbamate
Trial: 9430449
Drug: Human corticotropin-releasing
RxNorm normalized name: Human corticotropin-releasing factor
DrugBank: Corticorelin (DB05394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human corticotropin-releasing hormone (hCRH) 2.0 microg/kg i.v.
Trial: 9430449
Drug: Hexarelin (HEX)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hexarelin (HEX) and AVP co-administration
Trial: 9430449
Drug: Hexarelin (HEX)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hexarelin (HEX) and hCRH co-administration
Trial: 9430449
Drug: CRH and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CRH and AVP co-administration
Trial: 8495455
Drug: Propranolol LA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol LA 80 mg once daily
Trial: 8495455
Drug: Propranolol LA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol LA 160 mg once daily
Trial: 3003166
Drug: Water Pik
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water Pik oral irrigator
Trial: 25218827
Drug: Gabapentin 900
RxNorm normalized name: gabapentin 900 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin 900 mg + Donepezil 5 mg
Trial: 22931620
Drug: Oral intestinal
RxNorm normalized name: pork intestine preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral intestinal probiotics (Jinshuangqi Tablets, 2.0 g, 3 times daily)
Trial: 22931620
Drug: Oral intestinal
RxNorm normalized name: pork intestine preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral intestinal antimicrobial agents
Trial: 17240625
Drug: Anagrelide treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anagrelide treatment
Trial: 8861742
Drug: Minocycline (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minocycline (100 mg twice a day)
Trial: 1462746
Drug: 5‐FU alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5‐FU alone (440 mg/m2 IV bolus 5/21 days)
Trial: 1462746
Drug: Folinic acid
RxNorm normalized name: Folinic acid
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Folinic acid (200 mg/m2 IV bolus 5/21 days) preceding 5‐FU (370 mg/m2 in short infusion 5/21 days)
Trial: 1462746
Drug: Immediate post‐operative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate post‐operative continuous portal infusion (5‐FU 500 mg/m2/day x 7 followed by a 2 hours infusion of mitomycin C 10 mg/m2)
Trial: 31412688
Drug: Consumption of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Consumption of vegetables (41.28 g per portion at T0)
Trial: 31412688
Drug: Consumption of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Consumption of vegetables (36.67 g per portion at T1)
Trial: 31412688
Drug: Consumption of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Consumption of fruit (15.25 g per portion at T1)
Trial: 31412688
Drug: Healthy Eating
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Healthy Eating Index (39.26 g per 10 points at T0)
Trial: 31412688
Drug: Healthy Eating
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Healthy Eating Index (42.76 g per 10 points at T1)
Trial: 31412688
Drug: Sugar-sweetened beverages
RxNorm normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar-sweetened beverages (10.90 g per portion at T0)
Trial: 31412688
Drug: Sugar-sweetened beverages
RxNorm normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar-sweetened beverages (8.19 g per portion at T1)
Trial: 31412688
Drug: Higher sugar
RxNorm normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher sugar consumption at T0 (8.27 g per 10 g)
Trial: 31412688
Drug: Early pregnancy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early pregnancy alcohol intake (15.32 g per g)
Trial: 26509229
Drug: 1×15 minutes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1×15 minutes application of 35% hydrogen peroxide gel
Trial: 26509229
Drug: 2×15 minutes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2×15 minutes application of 35% hydrogen peroxide gel
Trial: 26509229
Drug: 3×15 minutes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3×15 minutes application of 35% hydrogen peroxide gel
Trial: 10085475
Drug: 0.6 mg/cm2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.6 mg/cm2 melatonin applied 15 min before UV irradiation
Trial: 8536413
Drug: Absolute leucocyte
RxNorm normalized name: Honey Absolute
DrugBank: Honey (DB14242)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Absolute leucocyte differential counts (cells x 10(9)/l)
Trial: 1703769
Drug: Secondary CHOP
RxNorm normalized name: Secondary potassium phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Secondary CHOP treatment
Trial: 1703769
Drug: Secondary CisEBP
RxNorm normalized name: Secondary potassium phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Secondary CisEBP treatment
Trial: 31474260
Drug: Fixed palatal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed palatal crib (FPC) treatment (TG)
Trial: 23356210
Drug: ASKP1240 (0.00003‐10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASKP1240 (0.00003‐10 mg/kg)
Trial: 20137402
Drug: Intrarectal lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrarectal lidocaine gel plus PNB (Group C)
Trial: 18196620
Drug: rosuvastatin 10
RxNorm normalized name: rosuvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rosuvastatin 10 mg once daily
Trial: 18196620
Drug: atorvastatin 10
RxNorm normalized name: atorvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: atorvastatin 10 mg once daily
Trial: 15071604
Drug: alemtuzumab (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alemtuzumab (30 mg i.v. TIW, 12 weeks)
Trial: 1671346
Drug: Immediate intravenous
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate intravenous metoprolol (15 mg IV over 6 minutes, followed by 50 mg orally every 12 hours for 24 hours, then 100 mg orally every 12 hours)
Trial: 1671346
Drug: Deferred metoprolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deferred metoprolol (50 mg orally twice on day 6, then 100 mg orally twice a day thereafter)
Trial: 6883915
Drug: Zomepirac (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zomepirac (400 mg and 800 mg)
Trial: 6883915
Drug: Morphine (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine (15 mg and 30 mg)
Trial: 26314234
Drug: Control (contrast
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (contrast agent)
Trial: 22459201
Drug: 0.42 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.42 mg/kg d‐methamphetamine
Trial: 20458441
Drug: Enoxaparin 80
RxNorm normalized name: ENOXAPARIN 80MG/0.8ML INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin 80 mg
Trial: 17122975
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of virtual reality training and inanimate box training
Trial: 16115831
Drug: Two intramuscular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two intramuscular doses of 12 mg betamethasone in the 48 hours before delivery
Trial: 8640466
Drug: Early oral
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early oral hydration (sips of fruit juices sweetened with honey, solid food 24 hours later)
Trial: 8640466
Drug: Conventional intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional intravenous hydration (2-3 L of dextrose saline/24 hours, solid food thereafter)
Trial: 8640466
Drug: Early oral
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early oral hydration
Trial: 2174277
Drug: Regimens including
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimens including radiotherapy after chemotherapy
Trial: 30056127
Drug: Single-dose 0.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose 0.5% ropivacaine paravertebral block (PVB) with patient-controlled intravenous analgesia (PCIA)
Trial: 30056127
Drug: Single-dose 0.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose 0.5% ropivacaine and dexmedetomidine (1 μg/kg) PVB with PCIA
Trial: 30056127
Drug: Intraoperative thoracic
RxNorm normalized name: Thoracol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative thoracic epidural anesthesia with 0.5% ropivacaine and single dose of epidural morphine (0.03 mg/kg) with PCIA
Trial: 25250722
Drug: Low-dose intravenous
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose intravenous immunoglobulins (IVIG) treatment
Trial: 22708798
Drug: Aminolaevulinate photodynamic
RxNorm normalized name: aminolevulinate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aminolaevulinate photodynamic therapy (PDT)
Trial: 21698545
Drug: NY‐ESO‐1 protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NY‐ESO‐1 protein with ISCOMATRIX™ adjuvant (10 μg, 30 μg, or 100 μg)
Trial: 21698545
Drug: 100 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 μg un‐adjuvanted NY‐ESO‐1 protein
Trial: 21698545
Drug: 2 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 μg DTH protein
Trial: 21698545
Drug: DTH skin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTH skin testing with NY‐ESO‐1 protein (1 μg) or peptides (10 μg)
Trial: 17415632
Drug: Antibiotics as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics as adjunct therapy to conventional treatment (corticosteroids and 5-aminosalycilic acid)
Trial: 17415632
Drug: Antibiotics (short-term
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics (short-term trials of 5-14 days)
Trial: 10216089
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy plus 300 mg vitamin E twice daily (n = 9)
Trial: 10216089
Drug: In vitro
RxNorm normalized name: glucuronidase in vitro test
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In vitro vitamin E (50 micromol/L)
Trial: 10216089
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (n = 5)
Trial: 8848526
Drug: Bretazenil (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bretazenil (1 mg)
Trial: 28457318
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil supplementation (4.4 g daily providing 2.6 g eicosapentaenoic acid and 1.8 g docosahexaenoic acid)
Trial: 23934907
Drug: Well-functioning implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Well-functioning implants
Trial: 23934907
Drug: Sub-optimal functioning
RxNorm normalized name: Optima Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sub-optimal functioning implants
Trial: 20647959
Drug: Hormone therapy
RxNorm normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hormone therapy (HT) users with CRP levels of 3 mg/L or higher
Trial: 20647959
Drug: Nonusers with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonusers with CRP levels of 3 mg/L or higher
Trial: 19662783
Drug: Budesonide/formoterol (640
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide/formoterol (640 mcg of budesonide and 18 mcg of formoterol daily)
Trial: 8948369
Drug: Nucleoside or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nucleoside or non-nucleoside analog reverse transcriptase inhibitors
Trial: 8948369
Drug: Combination nucleoside
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination nucleoside analog therapy
Trial: 8948369
Drug: Ritonavir (HIV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ritonavir (HIV protease inhibitor) monotherapy
Trial: 6185222
Drug: Tiapamil (0.3-1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiapamil (0.3-1.5 mg/kg bolus doses)
Trial: 6185222
Drug: Tiapamil (12-25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiapamil (12-25 mg/h continuous infusion)
Trial: 6185222
Drug: Tiapamil (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiapamil (1 mg/kg)
Trial: 6185222
Drug: Verapamil (0.13
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil (0.13 mg/kg)
Trial: 29848343
Drug: Music therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Music therapy (Trauma‐focused Music and Imagery, TMI)
Trial: 29848343
Drug: Verbal psychotherapy
RxNorm normalized name: HERBAL MISCELLANEOUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verbal psychotherapy (standard treatment)
Trial: 18315426
Drug: SDD-40 (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SDD-40 (40 mg doxycycline, once daily)
Trial: 17060062
Drug: olmesartan 20
RxNorm normalized name: olmesartan 20 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: olmesartan 20 mg plus glibenclamide 3.5 mg